m+Medelevator.RU
← Поиск публикаций
bioRxiv : the preprint server for biology · 2026

Conformational Basis of Functionally Selective Allosteric Modulation of the Angiotensin II type 1 Receptor by Small Molecules.

СтатьяПрепринтНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Liu Samuel, Xiao Peng, Elgeti Matthias, Fine Eve J, Lucero Emilio Y, Vestergaard Mikkel, Wang Junyan, Jyothidasan Arun, Li Angus, Qu Changxiu, Olsen Eva, Mazis Georgios, Madsen Josephine K, Suomivuori Carl-Mikael, Kim Jihee, Pakharukova Natalia, Rahman Rashad, Kereliuk Stephanie M, Koch Walter J, Strachan Ryan T, Staus Dean P, Masoudi Ali, Hubbell Wayne L, Kahsai Alem W, Dror Ron O, Rockman Howard A, Sun Jin-Peng, Ahn Seungkirl, Lefkowitz Robert J

Аннотация

Blockade of signaling through the angiotensin II type 1 receptor (AT1R), a prototypical G protein-coupled receptor (GPCR), by angiotensin receptor blockers (ARBs) is a major therapeutic approach to treating a wide variety of cardiovascular and renal diseases 1 . Like most GPCRs, the AT1R signals through two transducers, G proteins and β-arrestins 2,3 . Previous reports have described β-arrestin-biased peptide orthosteric agonists for the AT1R with potential therapeutic advantages over currently available unbiased ARBs 4-6 . Here we report the DNA- encoded library screening-guided isolation and pharmacological characterization of the first small molecule AT1R allosteric ligands. We use cryo-electron microscopy, double electron- electron resonance spectroscopy, molecular dynamics simulations, and targeted mutagenesis to determine their binding sites, binding modes and conformational mechanisms driving their unique and divergent modulatory effects on G protein and β-arrestin pathways. Our findings uncover new mechanisms for precisely controlling the dynamic behavior of the AT1R with implications for drug development targeting this pathophysiologically important receptor family.

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты